About My Health Careers Internship MedBlogs Contact us

Omecamtiv Mecarbil – Improves Survival in Heart Failure Patients

by Aishwarya Nair on November 25, 2020 at 12:46 AM
Font : A-A+

Omecamtiv  Mecarbil – Improves Survival in Heart Failure Patients

In the global approach to lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure( or GALACTIC-HF) multicentre trial the drug Omecamtiv Mecarbil was superior to placebo at improving cardiovascular outcomes in heart failure patients.

The GALACTIC-HF trial tested the hypotheses that omecamtiv mecarbil can safely improve symptoms, prevent clinical heart failure (HF) events, and delay cardio vascular death in patients with chronic HF. This was an international, multicentred, randomized double blind, placebo controlled trial. To understand heart failure one needs to understand that Ejection fraction (EF) is the key to the function of the heart. EF represents the proportion of blood that the heart pumps out after each contraction. In heart Failure the EF of a large left ventricle is inefficient in pumping the blood due to it's decreased contractility. EF of 40 % or less is usually defined as Heart Failure Ejection Fraction ( or FrEF)


A key factor in the pathogenesis of Heart Failure (HF) with reduced ejection Fraction is the initial decrease in the systolic or contraction function of the heart. There have been attempts to increase the cardiac contractility with oral drugs. However these drugs that increase the contractility ( so called ionotropic calcitropic drugs) have unfortunately resulted in increased mortality rates even at pharmacologically effective doses.

Omecamtiv mecarbil is a novel, selective cardiac myosin activator ( cardiac myosin - unit of heart muscle) that has shown to improve the cardiac function & decrease the ventricular cardiac myosin activator. At the same time it decreases ventricular volumes, heart rate & N-terminal pro-B-type natriuretic peptide in patients with chronic HF.

More than 8,000 patients with chronic symptomatic (NYHA Class II to IV) HF , with left ventricular ejection fraction ≤35%, elevated natriuretic peptides were randomized to either oral placebo or omecamtiv mecarbil employing a pharmacokinetic-guided dose titration strategy using doses of 25, 37.5, or 50 mg twice daily. These patients were either hospitalized for HF or had history of hospitalization or emergency department visit for HF within a year of screening.

The patients enrolled in the phase three had the following underlying conditions:
  • (78%), with an average age of 66 years, average ejection fraction of 27%,
  • 62% had coronary artery disease,
  • 40% had Type 2 diabetes,
  • 70 % had high BP ,
  • 36 % had chronic kidney disease
  • & 25 % were hospitalized at the time of enrolment.

The patients who received Omecamtiv mecarbil had a lesser risk of experiencing HF event or CV death. The medicine had a greater effect in patients with lower ejection fraction (an indicator of severe HF). The concentration of the Brain natriuretic peptide, a hormone that increases with worsening HF was reduced. There were no significant adverse effects reported. In addition the adverse effects like altered potassium levels, blood pressure , heart rate or kidney function that were typically seen with other drugs.

Teer link said, "This study provides substantial evidence characterizing the efficacy and safety of this novel therapy. The trial included a wide range of patients from both the inpatient and outpatient settings, and these findings will inform potential future implementation of omecamtiv mecarbil to treat chronic heart failure."

Source: Medindia

News A-Z
News Category
What's New on Medindia
Black Pepper as Preventive Measure Against Omicron
FODMAP Diet: A Beginner's Guide
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Congenital Heart Disease Heart Healthy Heart Pulmonary Arterial Hypertension Statins Mitral Valve Prolapse Aortic Valve Stenosis Infective Endocarditis Cough Symptom Evaluation Pericarditis 

Recommended Reading
Delaying Valve Replacement During COVID-19 can be Deadly
Patients with severe aortic stenosis should undergo valve replacement surgery within 2 weeks. This ....
Reducing Sedentary Time Downs Heart Failure Risk In Senior Women
Sedentary behaviors increase the risk of heart failure among older women, in spite of the regular .....
Diabetes Drug Empagliflozin Treats and Reverses Heart Failure
Diabetes drug Empagliflozin, can help treat and reverse heart failure in both diabetic and ......
Aortic Valve Stenosis
Aortic valve Stenosis is an abnormal narrowing of the c valve. Symptoms include angina, and that of ...
Congenital Heart Disease
Heart diseases that are present at birth are called “ Congenital heart diseases”....
Cough Symptom Evaluation
Cough is a symptom of a condition usually affecting the respiratory tract. It may be acute or chroni...
Infective Endocarditis
Infective endocarditis has been arbitrarily categorized as acute or subacute based on the length of ...
Mitral Valve Prolapse
Mitral Valve Prolapse is a relatively common condition and causes leakage of blood through the valve...
Pericarditis occurs when the pericardium gets inflamed. Pericarditis is characterized by severe ches...
Pulmonary Arterial Hypertension
It can be a serious condition affecting the heart. It is defined as mean pulmonary arterial pressure...
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms bu...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use